Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.Nature Medicine|November 28, 2018
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancerKhyati N Shah, Roma Bhatt, Julia Rotow, et al.Cancer|August 26, 2025
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024Narjust Florez, Sandip Patel, Heather A Wakelee, et al.The Journal of Clinical Investigation|May 17, 2022
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerShigeki Nanjo, Wei Wu, Niki Karachaliou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobaccoEleonora Gariazzo, Arielle Elkrief, Kyle Concannon, et al.Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.Pageof 2